Anabolic bone formation via a site-specific bone-targeting delivery system by interfering with semaphorin 4d expression

Journal of Bone and Mineral Research

Volumn 30, Issue 2, 2015, Pages 286-296

  Zhang, Yufeng ^a   Wei, Lingfei ^a   Miron, Richard J ^a   Shi, Bin ^a   Bian, Zhuan ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Bone remodeling; Bone targeting; Osteoporosis; Semaphorin

Indexed keywords

DEXTRO ASPARTIC ACID OCTAPEPTIDE; DRUG CARRIER; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; NANOCARRIER; SEMAPHORIN; SEMAPHORIN 4D; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CD100 ANTIGEN; LEUKOCYTE ANTIGEN; POLYMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE CHARACTERISTICS AND FUNCTIONS; BONE DEVELOPMENT; BONE MASS; BONE MATURATION; BONE REMODELING; BONE SURFACE; CELL COMMUNICATION; CELL MIGRATION; CONTROLLED STUDY; DRUG DISTRIBUTION; FEMALE; GENE EXPRESSION; MOUSE; NANOPHARMACEUTICS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCLAST ACTIVITY; OVARIECTOMY-INDUCED OSTEOPOROSIS; PHENOTYPE; RNA INTERFERENCE; SIGNAL TRANSDUCTION; ANIMAL; BONE DISEASES, METABOLIC; CELL DIFFERENTIATION; COCULTURE; CYTOLOGY; DISEASE MODEL; DRUG DELIVERY SYSTEM; GENETIC TRANSFECTION; METABOLISM; OSTEOPOROSIS; PATHOLOGY; PROCEDURES;

ANIMALS; ANTIGENS, CD; BONE DISEASES, METABOLIC; CELL DIFFERENTIATION; COCULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FEMALE; MICE; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; OSTEOPOROSIS; POLYMERS; RNA, SMALL INTERFERING; SEMAPHORINS; TRANSFECTION;

EID: 84921810091     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2322     Document Type: Article

References (29)

1. Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013;19(2):179-92.
2. Genant HK, Cooper C, Poor G, et al. Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int. 1999;10(4):259-64.
3. Silva BC, Bilezikian JP. New approaches to the treatment of osteoporosis. Annu Rev Med. 2011;62:307-22.
4. Wang Y, Li Z, Han Y, Liang LH, Ji A. Nanoparticle-based delivery system for application of siRNA in vivo. Curr Drug Metab. 2010;11(2):182-96.
5. Howard KA, Kjems J. Polycation-based nanoparticle delivery for improved RNA interference therapeutics. Expert Opin Biol Ther. 2007;7(12):1811-22.
6. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8(2):129-38.
7. Irie N, Takada Y, Watanabe Y, et al. Bidirectional signaling through ephrinA2-EphA2 enhances osteoclastogenesis and suppresses osteoblastogenesis. J Biol Chem. 2009;284(21):14637-44.
8. Sutton AL, Zhang X, Dowd DR, Kharode YP, Komm BS, Macdonald PN. Semaphorin 3B is a 1,25-Dihydroxyvitamin D3-induced gene in osteoblasts that promotes osteoclastogenesis and induces osteopenia in mice. Mol Endocrinol. 2008;22(6):1370-81.
9. Takegahara N, Takamatsu H, Toyofuku T, et al. Plexin-A1 and its interaction with DAP12 in immune responses and bone homeostasis. Nat Cell Biol. 2006;8(6):615-22.
10. Zhao C, Irie N, Takada Y, et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab. 2006;4(2):111-21.
11. Negishi-Koga T, Shinohara M, Komatsu N, et al. Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med. 2011;17(11):1473-80.
12. Leah E. Bone: finding that osteoclasts repel osteoblast activity through Sema4D reveals novel target for bone-boosting therapies. Nat Rev Rheumatol. 2011;7(12):681.
13. Delorme G, Saltel F, Bonnelye E, Jurdic P, Machuca-Gayet I. Expression and function of semaphorin 7A in bone cells. Biol Cell. 2005;97(7):589-97.
14. Fukuda T, Takeda S, Xu R, et al. Sema3A regulates bone-mass accrual through sensory innervations. Nature. 2013;497(7450):490-3.
15. Hayashi M, Nakashima T, Taniguchi M, Kodama T, Kumanogoh A, Takayanagi H. Osteoprotection by semaphorin 3A. Nature. 2012;485(7396):69-74.
16. Ohlsson C. Bone metabolism in 2012: novel osteoporosis targets. Nat Rev Endocrinol. 2013;9(2):72-4.
17. Larrivee B, Freitas C, Suchting S, Brunet I, Eichmann A. Guidance of vascular development: lessons from the nervous system. Circ Res. 2009;104(4):428-41.
18. Suzuki K, Kumanogoh A, Kikutani H. Semaphorins and their receptors in immune cell interactions. Nat Immunol. 2008;9(1):17-23.
19. Tran TS, Kolodkin AL, Bharadwaj R. Semaphorin regulation of cellular morphology. Annu Rev Cell Dev Biol. 2007;23:263-92.
20. Huber AB, Kolodkin AL, Ginty DD, Cloutier JF. Signaling at the growth cone: ligand-receptor complexes and the control of axon growth and guidance. Annu Rev Neurosci. 2003;26:509-63.
21. Dickson BJ. Molecular mechanisms of axon guidance. Science. 2002;298(5600):1959-64.
22. Tamagnone L, Comoglio PM. Signalling by semaphorin receptors: cell guidance and beyond. Trends Cell Biol. 2000;10(9):377-83.
23. Janssen BJ, Robinson RA, Perez-Branguli F, et al. Structural basis of semaphorin-plexin signalling. Nature. 2010;467(7319):1118-22.
24. Dacquin R, Domenget C, Kumanogoh A, Kikutani H, Jurdic P, Machuca-Gayet I. Control of bone resorption by semaphorin 4D is dependent on ovarian function. PLoS One. 2011;6(10):e26627.
25. Wang D, Sima M, Mosley RL, et al. Pharmacokinetic and biodistribution studies of a bone-targeting drug delivery system based on N-(2-hydroxypropyl)methacrylamide copolymers. Mol Pharm. 2006;3(6):717-25.
26. Tonges L, Lingor P, Egle R, Dietz GP, Fahr A, Bahr M. Stearylated octaarginine and artificial virus-like particles for transfection of siRNA into primary rat neurons. RNA. 2006;12(7):1431-8.
27. Zhang Y, Cheng N, Miron R, Shi B, Cheng X. Delivery of PDGF-B and BMP-7 by mesoporous bioglass/silk fibrin scaffolds for the repair of osteoporotic defects. Biomaterials. 2012;33(28):6698-708.
28. Wathen CA, Foje N, Avermaete TV, et al. In vivo X-ray computed tomographic imaging of soft tissue with native, intravenous, or oral contrast. Sensors. 2013;13(6):6957-80.
29. Zhang G, Guo B, Wu H, et al. A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy. Nat Med. 2012;18(2):307-14.